Home › Chronic Myelomonocytic Leukemia › Texas
Chronic Myelomonocytic Leukemia clinical trials in Texas
18 studies for Chronic Myelomonocytic Leukemia are looking for participants at sites in Texas.
Cities in Texas
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- MD Anderson Cancer Center, Houston
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT03383575Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07033598Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- AIR Care, Dallas
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- M D Anderson Cancer Center, Houston
RecruitingPhase 2/3Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 11, 2026 · NCT04708054Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 12 to 80 · All sexes · Updated Aug 7, 2026 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 15 to 80 · All sexes · Updated Jul 30, 2026 · NCT02727803Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT07128381A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT04239157CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT03896269A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Apr 30, 2026 · NCT04256317Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT04140487A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
RecruitingPhase 2
Ages 18 to 66 · All sexes · Updated Mar 17, 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Mar 16, 2026 · NCT06994676A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 9, 2026 · NCT06950034Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- MD Anderson Cancer Center, Huston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 26, 2025 · NCT03850574From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.